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Abstract
Purpose From 2010 until July 2016, the EANM Research
Ltd. (EARL) FDG-PET/CT accreditation program has col-
lected over 2500 phantom datasets from approximately
200 systems and 150 imaging sites worldwide. The
objective of this study is to report the findings and impact
of the accreditation program on the participating PET/CT
systems.
Methods To obtain and maintain EARL accredited status,
sites were required to complete and submit two phantom scans
- calibration quality control (CalQC), using a uniform cylin-
drical phantom and image quality control (IQQC), using a
NEMA NU2–2007 body phantom. Average volumetric SUV
bias and SUV recovery coefficients (RC) were calculated and
the data evaluated on the basis of quality control (QC) type,
approval status, PET/CTsystemmanufacturer and submission
order.
Results SUV bias in 5% (n = 96) of all CalQC submissions
(n = 1816) exceeded 10%. After corrective actions follow-
ing EARL feedback, sites achieved 100% compliance with-
in EARL specifications. 30% (n = 1381) of SUVmean and
23% (n = 1095) of SUVmax sphere recoveries from IQQC
submissions failed to meet EARL accreditation criteria
while after accreditation, failure rate decreased to 12%
(n = 360) and 9% (n = 254), respectively. Most systems
demonstrated longitudinal SUV bias reproducibility within
±5%, while RC values remained stable and generally within
±10% for the four largest and ±20% for the two smallest
spheres.
Conclusions Regardless of manufacturer or model, all inves-
tigated systems are able to comply with the EARL specifica-
tions. Within the EARL accreditation program, gross PET/CT
calibration errors are successfully identified and longitudinal
variability in PET/CT performances reduced. The program
demonstrates that a harmonising accreditation procedure is
feasible and achievable.
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Introduction
Positron emission tomography (PET) and computed tomography
(CT) hybrid imaging (PET/CT) using 18F–fluorodeoxyglucose
(FDG) has become a routinely used and valuable tool in oncol-
ogy. It is widely utilised for diagnosis, staging and restaging of
various malignancies [1–12] as well as response monitoring due
to its ability to measure metabolic changes [13–19]. Standard
uptake value (SUV), which represents the tissue radioactivity
concentration normalised to injected activity and body weight
[20] is the most frequently used quantitative metric in oncology
[21, 22]. Multiple factors, however, can give rise to bias [23–25]
and increased variability in SUV, especially when inter-centre
comparison is required from institutions lacking a uniform ap-
proach to imaging procedures [26–28]. The variability is a sig-
nificant issue for clinical trials or multicentre studies utilising the
quantitative potential of PET [24, 26–31]. In clinical practice,
there is a wide range of PETsystems installed globally including
scanners developed more than 10 years ago along with brand
new devices incorporating state of the art acquisition (i.e., time of
flight, digital PET detectors) and reconstruction (i.e., resolution
modelling) technologies [32]. In addition to various PET/CT
models available, the acquisition and reconstruction parameters
applied at different sites vary greatly due to local preferences [24,
32, 33]. Centres equipped with PET systems having new acqui-
sition and reconstruction technologies available, often tend to
aim for the possible best lesion detection, which may not be in
line with quantitative harmonising standards [34]. The aforemen-
tioned technical factors impose a significant source of variability
in PET quantification [24, 32] that should be addressed by the
international community.
Numerous professional societies and organisations such as
the Society of Nuclear Medicine and Molecular Imaging
(SNMMI), American College of Radiology Imaging
Network (ACRIN), Radiological Society of North America -
Quantitative Imaging Biomarkers Alliance (RSNA-QIBA),
The American Association of Physicists in Medicine
(AAPM) and the European Association of Nuclear Medicine
(EANM) are promoting harmonisation of imaging procedures
[35–37] in order to reduce the variability of PET image quan-
tification in a multicentre setting.Many of these programs rely
on quality control procedures utilising standard phantoms [38]
for standardisation of quantification [32, 39–41] and
harmonisation of PET/CT systems [35]. Review papers on
describing some of the results and experience in running such
programs have been published by Scheuermann et al. [39] and
more recently by Sunderland et al. [32].
In 2006, the European Association of Nuclear Medicine
(EANM) launched the EANM Research Ltd. (EARL) initia-
tive. One of the main objectives of the program has been
promoting multicentre nuclear medicine and research. In
2010, the FDG-PET/CT accreditation program was created
in order to address variability in the quickly growing field of
quantitative FDG-PET imaging by setting up guidelines and
specifications to which the participating sites must adhere.
The bandwidths for the current EARL specifications were
developed during a pilot study in 2010–2011 involving 12
PET/CT systems. Based on this study, specifications for
SUVmean and SUVmax recovery coefficients were derived,
which accommodated all investigated systems. From its initi-
ation until July 2016, EARL has collected approximately
2500 phantom datasets from more than 200 PET/CT systems
from over 150 imaging sites worldwide. The data analysed by
EARL encompasses the majority of the system types in clin-
ical use over the past 10 years and incorporates sites with
various backgrounds giving it a broad basis to represent the
field as a whole.
The objective of this paper is to report the findings obtained
so far in the EARL standardisation program and their impact
on the quantitative variability of accredited PET/CT systems.
Analysis of phantom scans from the largest number of active
PET centres so far provides representative details of current
quantitative capabilities of FDG-PET imaging and the vari-
ability to be expected. Understanding the characteristics of
variability and the impact on standardisation will help plan-
ning multi-centre clinical trials, utilising quantitative FDG-
PET/CT imaging and advance use of PET as a quantitative
imaging biomarker.
The secondary objective of this study is to explore ways to
improve the EARL FDG-PETaccreditation program based on
the retrospective analysis of phantom data collected in the
EARL database.
Materials and methods
Acquisition and submission of data to EARL
Sites, which are seeking EARL FDG-PET/CT accreditation
for the first time, need to pass the initial procedure. This pro-
cedure includes the submission of an online questionnaire and
a signed statement – these documents have to be submitted at
the start of the accreditation procedure and revised annually,
whereas QC documents need to be regularly provided in order
to maintain the EARL accredited status.
For the first and follow-up procedures, sites have to per-
form calibration QC and image quality QC measurements.
The calibration QC measurements have to be repeated every
3 months and image quality QC procedures annually, while
the data needs to be provided to EARL upon completion of the
procedures. During each round of QC survey, there is a 3 week
period for the sites to collect the data and submit it to EARL,
followed by a 3 week period of analysing the data by EARL
and reporting the results back to the sites.
For the calibration QC measurements, centres are asked to
use a cylindrical phantom with the following characteristics:
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diameter of about 20 cm (17 to 22 cm) and length sufficient to
cover the entire axial field of view (FOV). Furthermore, the
exact volume of the calibration phantom should be known and
recorded in the calibration QC scan report form. The phantom
has to be filled with water and about 70MBq 18F–FDG added
to it, aimed at expected phantom acquisition time.
For image quality QC measurements, the NEMA NU2–
2007 image quality phantom is required. The phantom has a
fillable torso cavity to act as a background compartment, a
5 cm diameter cylindrical lung insert in the centre and six
fillable spheres with internal diameters of 10 mm, 13 mm,
17 mm, 22 mm, 28 mm and 37 mm positioned coaxially
around the lung insert. The phantom background compart-
ment and the spherical inserts have to be filled with 18F–
FDG solution aimed at activity concentrations at the start of
the PET scan of 2 kBq/mL and 20 kBq/mL, respectively,
resulting in a sphere to background ratio of 10:1.
With both phantoms, routine quantitative whole body PET/
CTscans have to be performed with two PET bed positions of
at least 5 min each, including a (low dose) CT for attenuation
correction purposes [35]. After reconstruction, the attenuation
corrected PET, non-attenuation corrected PET and CT images
of the phantoms have to be uploaded into the EARL central
database, along with scan report forms.
Quantitative analysis and approval by EARL
The uniform calibration QC phantom and NEMA NU2 IQ
body phantom images uploaded into the EARL database are
evaluated centrally, making use of a standardised semi-
automatic quantitative analysis tool developed internally with-
in EARL. The software uses activity and time information
provided by the scan report forms. The average volumetric
SUV bias is generated as relative deviation between measured
and calculated activity concentration values (Eq. 1). The SUV
recovery coefficients (RCs) for the six spherical inserts are
based on 50% background corrected isocontour VOI
(RCSUVmean) and maximum voxel value included in the VOI
(RCSUVmax).
SUVbias %ð Þ ¼ Cmeasured
Ccalculated
−1
 
 100%; ð1Þ
, where
Cmeasured−activity concentration measured from images
Ccalculated−activity concentration calculated from injection data
EARL is applying SUV bias and RC values acceptance
criteria, which were defined by feasibility studies performed
on the systems used in clinical practices at the start of the
standardisation - a study is underway in order to update these.
When approval is not granted, the site undergoing
(re-)accreditation is asked to take corrective actions, for exam-
ple: recalibration of the PETsystem, adjustment of reconstruc-
tion parameters, repeating the phantom scan and so on. When
required, EARL is advising the sites. AManual describing the
accreditation program in detail as well as information on the
EARL website [42] is also available. If submitted QC docu-
ments meet the standard requirements, FDG-PET/CT accred-
itation is granted, and the department is listed on the EARL
website (http://earl.eanm.org) as an accredited PET/CT centre
of excellence. Furthermore, the site is provided with an ac-
creditation certificate and signet, which can be used on its
correspondence and website.
Data clean-up and preparation
To allow for data extraction, the EARL database had to be
cleaned of duplicates and entries with insufficient or missing
information removed, entry errors were identified and the in-
dividual site identification data ignored thereby providing an
anonymised set of data for evaluation. First and subsequent
site submissions were identified and marked as such.
Analysis
The calibration QC and image quality QC datasets from the
EARL database will be analysed based on the type of the
phantom, accreditation approval status, manufacturer of the
PET/CT system and whether it was the first or a subsequent
QC data submission. The SUV bias and normalised SUV
biases were analysed as well as the recovery coefficients for
each sphere size, separately for SUVmean and SUVmax. For
each parameter, mean, median, standard deviation, standard
error and skewness were calculated. Longitudinal reproduc-
ibility analysis was performed on 16 systems (systems A to P)
selected based on each having sufficient longitudinal data of at
least 18 approved CalQC data submissions or at least five
approved IQQC datasets.
Results
General overview
Data reviewed in this paper encompasses all submissions to
the EARL database from the initiation of the standardisation
program in November 2010 to July 2016. Figure 1 represents
the number of sites and systems participating each year. After
correcting for erroneous, partial and duplicate entries, 1816
CalQC and 778 IQQC datasets were used for further analysis.
The datasets were 29% (n = 752) from GE-, 29% (n = 741)
from Philips- and 42% (n = 1101) from Siemens-systems.
First data submissions constitute 10% (n = 175) of all
CalQC and 23% (n = 178) of all IQQC scans. 85%
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(n = 149) of the first and 94% (n = 1537) of subsequent CalQC
data submissions could be approved by EARL. This results in
an overall approval rate for CalQC of 93% (n = 1686). Table 1
states descriptive statistics for CalQC initial and subsequent
submissions.
Out of all systems (n = 200) that have enrolled in the pro-
gram, the accreditation for 47 systems (24%) has been
discontinued for various reasons, such as scanner replacement
or stopped participation in trials requiring EARL accreditation.
Calibration QC
Detailed descriptive statistics for CalQC SUV bias are
summarised in Table 1. Figure 2 demonstrates CalQC SUV
bias distribution for all, initial and subsequent submissions
along with vendor based distribution of approved results. It
was found 3% (n = 60) of all CalQC submissions were below
and 2% (n = 36) above the corresponding EARL SUV bias
limits of −10% and +10%. Also, 9% (n = 16) of systems could
not be approved at first CalQC submission, but after corrective
actions all of the scanners fulfilled the EARL specifications.
Significant mean SUV biases of −1.53% (p < 0.0001) and
−1.78% (p < 0.0001) were observed in approved datasets from
GE and Philips systems, respectively, while datasets from
Siemens systems did not demonstrate this deviation. In
Fig. 3 longitudinal CalQC volumetric SUV bias is plotted as
a function of the order of subsequent submissions.
Image quality QC
Descriptive statistics for IQQC SUVmax and IQQC
SUVmean results for each sphere size are summarised in
Supplemental Tables 1 and 2. Figure 4 shows the distribution
of sphere recoveries of all submitted data and approved IQQC
submissions along with SUVrecovery distributions separately
per manufacturer. A large variability in sphere recoveries was
observed. Out of all sphere recoveries from IQQC datasets,
30% (n = 1381) of SUVmean and 23% (n = 1095) of SUVmax
recoveries failed to meet the EARL accreditation criteria.
After corrective actions the corresponding values dropped to
12% (n = 360) and 9% (n = 254) respectively. A positive bias
in the recovery values was observed prior to and also after the
corrective actions and granted accreditation, respectively. 47%
(n = 84) of sites’ initial IQQC submissions and 68% (n = 409)
of all consecutive IQQC submissions were approved by
EARL. Overall approval rate for IQQC submissions was
63% (n = 493).
To evaluate the longitudinal performance of the 16 sys-
tems, sphere recoveries for all sphere sizes were plotted based
on the order of subsequent submissions, as seen in Fig. 5.
From the figure, it can be seen that for each sphere there is
an initial large variability in observed SUV recoveries, which
is reduced and becomes harmonised during subsequent
submissions.
Discussion
The number of sites participating in the EARL accreditation
program is steadily increasing and the received data is almost
equally distributed among the three major PET/CT system
manufacturers.
Inconsistency was observed in the names provided for
same types of systems and in some cases the device serial
numbers were missing or had been changed at the occasion
of software upgrade or service maintenance. This complicated
the distinction between new systems and those already
existing in the EARL database. As a solution, the EARL da-
tabase client portal could be configured so that the system type
selection be performed by choosing from a predefined list, in
the same way as it currently works for system manufacturer,
permitting that the regularly submitted QC data be checked
and, if necessary, corrected for constancy of the core data and
the device serial number in particular.
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A small number (n = 19) of calibration QC submissions
were not included in further analysis due to large SUV biases
observed. The high values might have been related to improp-
er data communication from the participants, inhomogeneous
phantoms or system failures left unnoticed by the centres. In
all these cases, sites were asked to implement corrective ac-
tions and redo the experiments. As a result, all of the affected
systems achieved compliance with the EARL specifications
and were granted accreditation.
Regardless of manufacturer or model, all systems were
able to comply with the CalQC specifications set up by
EARL. Only 9% of sites first QC submissions and 5% of
all CalQC submissions demonstrated a measured activity
bias of more than 10%. Scheuermann et al. in their re-
view of ACRIN PET Core Laboratory program reported
a similar initial SUV or normalisation calibration failure
rate of 12% within the same acceptance criteria of SUV
1.0 ± 0.1 [39].
Table 1 CalQC SUV bias statistics from first, regular ongoing and all EARL approved submissions (pooled and per vendor)
CalQC Mean SUV
bias (%)
Median
SUV
bias (%)
SUV bias
Std. Dev
(%)
Skewness Submissions
with SUV
bias below
EARL specs
Submissions
with SUV
bias above
EARL specs
Submissions
with SUV
bias within
EARL specs
All CalQC −1.14 (±0.13) −1.01 5.36 −0.32 3% 2% 95%
All approved CalQC −0.97 (±0.09) −0.94 3.71 0.15 0% 0% 100%
Sites’ first submitted CalQC −1.25 (±0.46) −0.79 6.06 −1.14 6% 3% 91%
Subsequent approved
submissions CalQC
−1.01 (±0.09) −1.02 3.66 0.16 0% 0% 100%
All approved GE CalQC −1.53 (±0.15) −1.60 3.27 0.31 0% 0% 100%
All approved Philips CalQC −1.78 (±0.18) −1.71 3.89 0.26 0% 0% 100%
All approved Siemens
CalQC
−0.05 (±0.14) 0.06 3.65 0.01 0% 0% 100%
All All approved Initial Subsequent approved GE approved Philips approved Siemens approved
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Fig. 2 Comparison of CalQC SUV bias distribution for all, initial and
subsequent submissions along with vendor based distribution of
approved results. The dotted horizontal lines represent EARL
specification limits. Central line of the box is the median, edges of the
box are the 25th and 75th percentiles, the whiskers extend to either of the
most extreme data points, which are not considered outliers or 1.5 times
interquartile range. The outliers are marked using plus signs
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Compared to all received data, the non-compliances were
almost eliminated in EARL approved data. In the datasets
reviewed and approved by EARL, all CalQC SUV biases fall
within the range of ±10.5%, which aligns with the target of
±10%. Although the fraction of non-approved data from com-
bined first and regular submissions was relatively small (about
5%), the importance of this fact should not be underestimated,
since noncompliance in calibration QC procedure means
gross error in basic system calibration, which would affect
all further PET quantitative evaluations.
CalQC average values demonstrate a slight but statistically
significant underestimation of the activity concentration or
SUV by Philips and GE systems, while data from Siemens
devices do not show this deviation. Scheuermann et al. report-
ed similar results for Philips systems [39]. Whether this is due
to some systematic differences among the vendors’ calibration
procedures, drifts in calibration values or some unknown ef-
fects, could not be derived from the current data but should be
subject for further investigations. However, it is important to
note that these errors were well within 2% and are very likely
to be clinically irrelevant.
Longitudinal analysis of the CalQC results from 16 select-
ed systems, visualised in Fig. 6, illustrates good performance
of the systems and reflects the quantification stability achieved
by the accredited sites. Large SUV biases were only occasion-
ally observed, and were all corrected by the sites after receiv-
ing notification from EARL. In most of the cases, corrective
action had been taken within 4 weeks.
The majority of PET/CT systems followed throughout the
investigation period showed good reproducibility of the
CalQC results seen in Fig. 3. Longitudinal SUV bias values
lie mostly within ±5% of the expected value, which is in
agreement with data published by Geworski et al. [43] and
more recently by Sunderland et al. [32]. The rest of the sys-
tems also meet the ±10% calibration accuracy criteria. Our
findings suggest opportunities for the implementation of
stricter accreditation specification for EARL CalQC SUV
biases.
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The comparison between all received and EARL approved
data indicates significant reduction of outliers for IQQC re-
sults (Supplemental Tables 1 and 2). However, some of the data
not strictly within EARL specifications was still accepted after
critical review. This means the noncompliant data was deemed
acceptable in case only one of the spheres being slightly out of
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the specifications, but the overall shape and magnitude of RC
curve could be determined to a sufficient extent and being
compliant with EARL criteria. Moreover, in these cases sub-
missions were reviewed retrospectively and consistency of ac-
quisition, reconstruction and settings was verified. While in
case of the larger diameter spheres meeting EARL specifica-
tions was common, for the smallest sphere (10 mm diameter)
SUVmax data remained outside of specified bandwidth in 26%
of the EARL approved submissions. Achieving harmonised
quantitative results for the smallest sphere turned out to be
challenging due to its increased sensitivity to image noise and
phantom positioning within the PET field of view.
Although in most cases when the spheres’ RCs did not
meet the specifications, sites were asked to redo experiments,
still a noticeable upward bias in results for the smallest sphere
could be observed. Therefore, based on these findings EARL
implemented slightly adjusted recovery specifications for the
smallest sphere starting from the 1st of January 2017.
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Prior to harmonisation, the average recoveries of all
spheres demonstrated a positive bias compared to EARL spec-
ifications. The trend could still be observed to some extent
within the approved results. This can be attributed to both
the vendors and sites preferences leaning towards reconstruc-
tion algorithms emphasising contrast and detectability. The
positive bias in the case of the 10 mm diameter sphere might
also be attributed to newly adopted acquisition and reconstruc-
tion technologies (e.g., including resolution modelling),
which aims at increasing small lesion detectability. This trend
was also observed by Sunderland et al. who showed that re-
coveries were generally higher for systems employing TOF
and PSF reconstructions [32]. Since more modern PET/CT
systems with new technologies appear in the field, a review
of the existing EARL specifications is required in order to
facilitate the inclusion of the increased contrast recovery ca-
pabilities of these systems. EARL is currently carrying out a
feasibility study aiming at redefining the accreditation criteria
by taking into account not only the new technologies but also
considering that the majority of the PET/CTsystems currently
in clinical use should be able to comply.
By comparing the first and following regular submissions
from participating sites, a relative increase can be observed in
meeting the EARL specifications which is expected since the
accredited sites gain experience in performing quantitative cal-
ibrations and assessment of their systems. The staff’s increased
awareness towards the necessity of regular calibration and
quality control of the systems is one of the benefits of partici-
pation in an accreditation/standardisation program, which is
difficult to measure but should not be underestimated.
IQQC longitudinal analysis results, presented in Fig. 5
visualise the major improvement of regular submissions in
relation to the first submission. As the sphere size decreases,
the improvement becomes more prominent. After initial ad-
justment of the reconstruction parameters, the longitudinal
reproducibility remains stable and generally within ±10% for
the largest four spheres and ±20% for the smallest two
spheres. These findings emphasise that PET/CT performance
and the execution of the QC experiments show high reproduc-
ibility and demonstrate that long-term maintenance of a
harmonised PET/CT network is feasible and achievable.
Conclusion
The European Association of Nuclear Medicine (EANM) has
been running an FDG-PET/CT accreditation program under
the EANM Research Ltd. (EARL) initiative in order to har-
monise quantitative PET/CT performance and facilitate multi-
centre nuclear medicine and research. The number of sites and
systems participating in the accreditation program has steadily
increased over the years with similar numbers of scanners
from each of the three major vendors.
Outliers observed in the overall submissions of both CalQC
and IQQC were largely eliminated in subsequent submissions
after notification from EARL. Excellent longitudinal perfor-
mance was observed in most of the systems – a majority
demonstrated CalQC values reproducible within 5% and
IQQC results within 10% for the largest four spheres and
20% for the smallest two spheres. Occasional deviations from
expected values were rapidly resolved by the sites after noti-
fication from EARL. Regardless of system manufacturer or
model, all vendors were able to comply with the accreditation
specifications set out by EARL.
Prior to harmonisation, IQQC data demonstrated a
slight positive bias relative to EARL specifications, which
suggested carrying out a review and an update in order to
account for the advances in acquisition and reconstruction
technologies in PET/CT.
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In this manuscript we have demonstrated that the EARL
accreditation program can successfully identify gross PET/CT
calibration errors and reduces variability in PET/CT perfor-
mance by longitudinally performing harmonisation QC exper-
iments. The program is running successfully for more than
6 years and shows that a harmonising accreditation procedure
is feasible and achievable.
Centres with accredited PET/CT systems benefit greatly
from participating in large-scale accreditation programs,
which facilitate the implementation of procedural guidelines
widely recognised by the imaging community.
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